NCT06245915
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorArsenal Biosciences, Inc.
Primary completion (estimated)
At risk: Primary completion moved 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Mar 31, 2026 to Dec 31, 2026
- Eligibility criteria expanded, about 15 words
- Study sites: 9 to 8
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 130 to confirmed 37
- Study sites revised (9)
- Minor Study description shortened, about 53 words
- Study title shortened, about 1 word
- Notable Primary completion date: Feb 26, 2025 to Mar 31, 2026
- Study sites: 7 to 9
- Study completion date: May 31, 2027 to Jun 30, 2028
- Minor Study sites: 4 to 7v5
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 2 to 4v4
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Phase 1 (Dose escalation): incidence of adverse events
Timeframe: From AB-2100 infusion up to 21 days post infusion
Phase 2 (Cohort expansion): Objective response rate (ORR)
Timeframe: From AB-2100 infusion up to 24 months post-infusion
Arms and interventions
AB-2100Experimental
Patients receive a single dose of AB-2100 intravenously on day 0. Patients may be assigned to receive conditioning chemotherapy prior to the infusion.
Biologicals: AB-2100
Sites
8 sites in 1 country